Premium
The safety and effectiveness of a long‐acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical study
Author(s) -
Martinez S. A.,
Wilson M. G.,
Linton D. D.,
Newbound G. C.,
Freise K. J.,
Lin T.L.,
Clark T. P.
Publication year - 2014
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12096
Subject(s) - oxymorphone , medicine , anesthesia , fentanyl , adverse effect , randomized controlled trial , confidence interval , transdermal , surgery , opioid , pharmacology , oxycodone , receptor
A prospective, double‐blinded, positive‐controlled, multicenter, noninferiority study was conducted to evaluate the safety and effectiveness of transdermal fentanyl solution ( TFS ) compared with oxymorphone for the control of postoperative pain in dogs. Five hundred and two (502) client‐owned dogs were assigned to a single dose of TFS (2.7 mg/kg) applied 2–4 h prior to surgery or oxymorphone hydrochloride (0.22 mg/kg) administered subcutaneously 2–4 h prior to surgery and q6h through 90 h. Pain was evaluated over 4 days by blinded observers using a modified Glasgow composite pain scale, and the a priori criteria for treatment failure was a pain score ≥8 or adverse event necessitating withdrawal. Four TFS ‐ and eight oxymorphone‐treated dogs were withdrawn due to lack of pain control. Eighteen oxymorphone‐treated, but no TFS ‐treated dogs were withdrawn due to severe adverse events. The one‐sided upper 95% confidence interval of the difference between TFS and oxymorphone treatment failure rates was −5.3%. Adverse events associated with oxymorphone were greater in number and severity compared with TFS . It was concluded that a single administration of TFS was safe and noninferior to repeated injections of oxymorphone for the control of postoperative pain over 4 days at the dose rates of both formulations used in this study.